NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (NASDAQ: ZYME), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Jabil Inc. (NYSE: JBL), and DoubleVerify Holdings, Inc. (NYSE: DV). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Zymeworks Inc. (NASDAQ: ZYME)
On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle (“Astle”) from the positions of Senior Vice President (“SVP”) and Chief Financial Officer (“CFO”), effective immediately. Notably, although Zymeworks indicated that it had appointed current President and Chief Executive Officer Kenneth Galbraith as Interim CFO and had initiated a search for a new CFO, the Company failed to provide any reasoning for Astle’s removal as SVP and CFO.
On this news, Zymeworks’s stock price fell $0.64 per share, or 6.08%, to close at $9.88 per share on April 1, 2024.
For more information on the Zymeworks investigation go to: https://bespc.com/cases/ZYME
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
Regeneron is the subject of a DOJ lawsuit filed on April 10, 2024. The lawsuit accuses Regeneron of failing to report millions of dollars in discounts given to drug distributors. These discounts were provided as reimbursements for credit card processing fees. As a result, the DOJ alleges that the average selling price of Regeneron's Eylea drug was inflated above the amount allowed by Medicare.
For more information on the Regeneron investigation go to: https://bespc.com/cases/REGN
Jabil Inc. (NYSE: JBL)
On April 18, 2024, Jabil disclosed in filing with the U.S. Securities and Exchange Commission that "[o]n April 15, 2024, Mr. Kenneth S. Wilson, Chief Executive Officer and Director of [Jabil] was placed on a paid leave pending completion of an investigation related to corporate policies." Additionally, the Company represented that "[t]he conduct that prompted this review does not relate to, and does not impact, the Company's financial statements or financial reporting."
On this news, Jabil's stock price fell $10.84 per share, or 8.36%, to close at $118.75 per share on April 19, 2024.
For more information on the Jabil investigation go to: https://bespc.com/cases/JBL
DoubleVerify Holdings, Inc. (NYSE: DV)
On May 7, 2024, DoubleVerify announced its financial results for the first quarter of 2024, noting the Company was adjusting its “full-year 2024 guidance ranges to 17% revenue growth, and 31% adjusted EBITDA margins at the midpoints primarily due to uneven spending patterns among select large advertisers.”
On this news, the price of the Company’s stock dropped.
For more information on the DoubleVerify investigation go to: https://bespc.com/cases/DV
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
